Search research articles
Contact Us
Filters
Showing results (181-190 of 185) with videos related to
Page
of 19
Sort By:
You have reached the last page of results.
This site can display upto 185 results.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
May 4, 2019
Randomized phase III KEYNOTE-045 trial of pembrolizumab versus paclitaxel, docetaxel, or vinflunine in recurrent advanced urothelial cancer: results of >2 years of follow-up
Y Fradet, J Bellmunt, D J Vaughn, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
May 16, 2001
Viable malignant cells after primary chemotherapy for disseminated nonseminomatous germ cell tumors: prognostic factors and role of postsurgery chemotherapy--results from an international study group
K Fizazi, S Tjulandin, R Salvioni, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
April 20, 2016
Tumor heterogeneity of fibroblast growth factor receptor 3 (FGFR3) mutations in invasive bladder cancer: implications for perioperative anti-FGFR3 treatment
D Pouessel, Y Neuzillet, L S Mertens, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
August 21, 2004
European consensus on diagnosis and treatment of germ cell cancer: a report of the European Germ Cell Cancer Consensus Group (EGCCCG)
H J Schmoll, R Souchon, S Krege, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
November 20, 2019
EAU-ESMO consensus statements on the management of advanced and variant bladder cancer-an international collaborative multi-stakeholder effort: under the auspices of the EAU and ESMO Guidelines Committees†
A Horwich, M Babjuk, J Bellmunt, et al.
Page
of 19
Search research articles
Search
Showing results (181-190 of 185) with videos related to
Sort By:
Page
of 19
You have reached the last page of results.
This site can display upto 185 results.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
May 4, 2019
Randomized phase III KEYNOTE-045 trial of pembrolizumab versus paclitaxel, docetaxel, or vinflunine in recurrent advanced urothelial cancer: results of >2 years of follow-up
Y Fradet, J Bellmunt, D J Vaughn, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
May 16, 2001
Viable malignant cells after primary chemotherapy for disseminated nonseminomatous germ cell tumors: prognostic factors and role of postsurgery chemotherapy--results from an international study group
K Fizazi, S Tjulandin, R Salvioni, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
April 20, 2016
Tumor heterogeneity of fibroblast growth factor receptor 3 (FGFR3) mutations in invasive bladder cancer: implications for perioperative anti-FGFR3 treatment
D Pouessel, Y Neuzillet, L S Mertens, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
August 21, 2004
European consensus on diagnosis and treatment of germ cell cancer: a report of the European Germ Cell Cancer Consensus Group (EGCCCG)
H J Schmoll, R Souchon, S Krege, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
November 20, 2019
EAU-ESMO consensus statements on the management of advanced and variant bladder cancer-an international collaborative multi-stakeholder effort: under the auspices of the EAU and ESMO Guidelines Committees†
A Horwich, M Babjuk, J Bellmunt, et al.
Page
of 19